Get the Stockscreener App
0.711
1.07%
-0.0077
Cue Biopharma Inc stock is traded at $0.711, with a volume of 44,936.
It is down -1.07% in the last 24 hours and down -8.87% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.7187
Open:
$0.71
24h Volume:
44,936
Relative Volume:
0.17
Market Cap:
$54.38M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.7813
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
+0.44%
1M Performance:
-8.87%
6M Performance:
-5.20%
1Y Performance:
-1.21%
1-Day Range:
$0.6989
$0.7163
1-Week Range:
$0.6751
$0.7459
52-Week Range:
$0.5406
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.7077 | 55.23M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.00 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.01 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.13 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
768.98 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
343.34 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Reversal indicators forming on Cue Biopharma Inc. stockBond Market & Real-Time Stock Entry Alerts - newser.com
Will Cue Biopharma Inc. stock reach all time highs in 2025 - newser.com
Market reaction to Cue Biopharma Inc.’s recent newsDay Trade & Daily Profit Focused Screening - newser.com
Is Cue Biopharma Inc. (1UC) stock undervalued after correctionInsider Buying & Real-Time Buy Signal Notifications - newser.com
Cue Biopharma names Usman Azam as new CEO and president - The Pharma Letter
Will breakout in Cue Biopharma Inc. lead to full recoveryTrade Volume Report & Low Risk High Reward Ideas - newser.com
Is Cue Biopharma Inc. stock a top momentum playWeekly Investment Report & Fast Gain Stock Tips - newser.com
Building trade automation scripts for Cue Biopharma Inc.2025 Bull vs Bear & Consistent Income Trade Recommendations - newser.com
Cue Biopharma Appoints Usman “Oz” Azam, M.D., as CEO - citybiz
Cue Biopharma Appoints Usman Azam as New CEO - TipRanks
How Cue Biopharma Inc. (1UC) stock stacks up against competitorsMarket Performance Report & Fast Gain Swing Trade Alerts - newser.com
Cue Biopharma, Inc. Appoints Usman ?Oz? Azam, M.D. as President, Effective September 29, 2025 - MarketScreener
Cue Biopharma appoints new CEO, shifts focus to autoimmune therapies - MarketScreener
Cue Biopharma names Usman Azam as new CEO, shifts focus to autoimmune disease - Investing.com
Cue Biopharma appoints Usman Azam as CEO - TipRanks
Cue Biopharma Announces Strategic Transition in Leadership - GlobeNewswire
Former Novartis CAR-T Head Takes Helm at Cue Biopharma to Lead Revolutionary Autoimmune Drug Development - Stock Titan
GC Wealth Management RIA LLC Acquires New Stake in Cue Biopharma, Inc. $CUE - MarketBeat
How to build a custom watchlist for Cue Biopharma Inc.Weekly Volume Report & Risk Managed Investment Strategies - newser.com
What drives Cue Biopharma Inc stock priceBull Market Opportunities & Free High Frequency Trading Ideas - Early Times
Cue Biopharma (NASDAQ:CUE) Trading Up 2.9%What's Next? - MarketBeat
Cue names Daniel Baker interim CDO, CSO Anish Suri to transition to advisor role - MSN
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):